Boston, MA 02\/11\/2014 (wallstreetpr) –\u00a0Boston scientific Corporation (NYSE:BSX) <\/b>is finally making its mark in the medical device market at the back of some of the finest results in F2013. The turnaround begun with the company recording improved sales for the year that saw its full year revenue increase by 2% to reach highs of $7.143 billion. The slight improvement in its sales was greatly impacted by the growth being experienced in Endoscopy and peripheral division. Boston Scientific has already made 11 acquisition which it intends to use to make its mark in the market.<\/p>\n
\u00a0The past two years saw the sales of its largest division Interventional Cardiology and cardiac Rhythm management slump in the market to near double digits but not in F2013. The two segments recorded stability in the market a good sign they might be picking up very soon.<\/p>\n
Boston scientific Corporation (NYSE:BSX)<\/b> products have gained the much needed appeal in emerging markets and with the acceptance of its products at large, things can only get better in the near future. Backed by the new products the company continues to launch in the market, there is a huge belief the company is to experience sales growth of as high as 3% to 5% in F2014.<\/p>\n
\u00a0Some of the products sure to propel Boston Scientific in F2014 include:<\/p>\n
Synergy Stents<\/b><\/p>\n
Synergy stents received approval in Europe in F2012 and is on top of the list as one of the products expected to turn the fortunes of Boston Scientific. The Device is currently on the testing stage in America and should not fail any test as it has already passed the acid test in Europe. Synergy stent is basically a stent that readily dissolves in the body in three months.<\/p>\n
Promus stents<\/b><\/p>\n
Boston scientific Corporation (NYSE:BSX)<\/b> is currently producing this PROMUS drug eluting stent in house having previously outsourced it to Abbot Labs. PROMUS should perform extremely well in the market in the coming quarters having received FDA approval and just like Synergy, it is expected to be the driving force behind Boston Scientific growth.<\/p>\n
Vessix Renal Denervation System <\/b><\/p>\n
\u00a0With the increasing numbers of people being affected with high blood pressure, Boston scientific seems to have found the solution in the name of VRDS. This is an effective solution as it can readily use on patients who are resistant to oral hypertension drugs to successful outcomes.<\/p>\n
\u00a0Lotus Transcather Aortic valve device<\/b><\/p>\n
This is the device that can be used with utmost success on patients who can\u2019t undergo open heart surgeries. The device has already received approval and should start being used to impair heart valves in patients with heart diseases.<\/p>\n
Boston scientific Corporation (NYSE:BSX) <\/b>seems to have made the best strategies with their new set of products that have already had a major impact in the medical industry. This should essentially signal the start of increased profits in F2014 if the right marketing strategies are used.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 02\/11\/2014 (wallstreetpr) –\u00a0Boston scientific Corporation (NYSE:BSX) is finally making its mark in the medical device market at the back of some of the […]<\/p>\n","protected":false},"author":2,"featured_media":15089,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2960,1020],"stock_ticker":[],"class_list":["post-15088","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-boston-scientific-corporation-nysebsx","tag-nysebsx","entry"],"acf":[],"yoast_head":"\n